• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024 | Press Releases

Award is being presented during Advanced Therapies Week 2025 in DallasMarlborough, Massachusetts–(Newsfile Corp. – December 10, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Dec 3, 2024 | Press Releases

Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – December 3, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024 | Press Releases

–Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts–(Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a...

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – November 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing...

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024 | Press Releases

Presenting new clinical data from Phio’s on-going Phase 1b trialMarlborough, Massachusetts–(Newsfile Corp. – November 7, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Nov 1, 2024 | Press Releases

Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm ESTMarlborough Massachusetts–(Newsfile Corp. – November 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
  • Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
  • Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
  • Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2025 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us